Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech Ltd has won a major pre-clinical testing contract valued at ₹10.75 Crores for a novel molecule. The work is being done in collaboration with a leading Indian pharma and agro-chemical company. The scope includes toxicity studies, mutagenicity evaluations, ecotoxicology studies, and analytical services, with submissions planned under Section 9(3) to the Central Insecticides Board & Registration Committee (CIBRC). The contract runs for up to two years and is a domestic, non-related-party deal. Management says this places Vivo Bio Tech among a small group of Indian CROs capable of delivering end-to-end pre-clinical solutions.
Positive for the stock — this is a sizeable single contract win that strengthens the company's order book and reinforces its positioning as a full-service CRO, though its impact on full-year revenue will depend on execution over the two-year contract period.